Acute Leukemias - Republican Scientific Medical Library

More documents

Recommendations

Info

106 Chapter 6 · Molecular Biology and Genetics 88. Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H (1999) Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Mol Cell Biol 19(2):1171–1181 89. Barber KE, Martineau M, Harewood L, et al. (2004) Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 18(6):1153–1156 90. Graux C, Cools J, Melotte C, et al. (2004) Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 36(10):1084–1089 91. Heinonen K, Mahlamaki E, Riikonen P, Meltoranta RL, Rahiala J, Perkkio M (1999) Acquired X-chromosome aneuploidy in children with acute lymphoblastic leukemia. Med Pediatr Oncol 32(5):360–365 92. Onodera N, McCabe NR, Rubin CM (1992) Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood 80(1):203–208 93. Paulsson K, Panagopoulos I, Knuutila S, et al. (2003) Formation of trisomies and their parental origin in hyperdiploid childhood acute lymphoblastic leukemia. Blood 102(8):3010–3015 94. Czuczman MS, Dodge RK, Stewart CC, et al. (1999) Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and leukemia Group B study 8364. Blood 93(11):3931–3939 95. Harrison CJ, Moorman AV, Broadfield ZJ, et al. (2004) Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 125(5):552–559 96. Garipidou V, Yamada T, Prentice HG, Secker-Walker LM (1990) Trisomy 8 in acute lymphoblastic leukemia (ALL): A case report and update of the literature. Leukemia 4(10):717–719 97. Cario G, Stanulla M, Fine BM, et al. (2004) Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 105(2):821–826 98. Willenbrock H, Juncker AS, Schmiegelow K, Knudsen S, Ryder LP (2004) Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays. Leukemia 18(7):1270–1277 99. Tsukasaki K, Tanosaki S, DeVos S, et al. (2004) Identifying progression-associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays. Int J Cancer 109(6):875–881 100. Chiaretti S, Li X, Gentleman R, et al. (2004) Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 103(7):2771–2778 101. Mitchell SA, Brown KM, Henry MM, et al. (2004) Inter-platform comparability of microarrays in acute lymphoblastic leukemia. BMC Genomics 5(1):71 102. Holleman A, Cheok MH, den Boer ML, et al. (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351(6):533–542 103. Derynck R, Zhang YE (2003) Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature 425(6958):577–584 104. Wolfraim LA, Fernandez TM, Mamura M, et al. (2004) Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med 351(6):552–559 105. Armstrong SA, Kung AL, Mabon ME, et al. (2003) Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3(2):173–183 106. Taketani T, Taki T, Sugita K, et al. (2004) FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103(3):1085–1088 107. Armstrong SA, Mabon ME, Silverman LB, et al. (2004) FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103(9):3544–3546 108. Paietta E, Ferrando AA, Neuberg D, et al. (2004) Activating FLT3 mutations in CD117/KIt(+) T-cell acute lymphoblastic leukemias. Blood 104(2):558–560 109. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D (2004) FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105(2):812–820 110. Ferrando AA, Look AT (2003) Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol 40(4):274–280 111. Ferrando AA, Neuberg DS, Staunton J, et al. (2002) Gene expression signatures define novel oncogenic pathways in T-cell acute lymphoblastic leukemia. Cancer Cell 1(1):75–87 112. Ferrando AA, Neuberg DS, Dodge RK, et al. (2004) Prognostic importance of TLX1 (HOX11) oncogene expression in adults with Tcell acute lymphoblastic leukaemia. Lancet 363(9408): 535–536 113. Bernard OA, Busson-LeConiat M, Ballerini P, et al. (2001) A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 15(10):1495–1504 114. Berger R, Dastugue N, Busson M, et al. (2003) t(5;14)/HOX11L2positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Leukemia 17(9):1851–1857 115. Cave H, Suciu S, Preudhomme C, et al. (2004) Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: Results of EORTC studies 58881 and 58951. Blood 103(2):442– 450 116. Ballerini P, Blaise A, Busson-Le Coniat M, et al. (2002) HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 100(3):991–997 117. Weng AP, Ferrando AA, Lee W, et al. (2004) Activating mutations of NOTCH1 in human T-cell acute lymphoblastic leukemia. Science 306(5694):269–271 118. Pear WS, Aster JC (2004) T-cell acute lymphoblastic leukemia/ lymphoma: A human cancer commonly associated with aberrant NOTCH1 signaling. Curr Opin Hematol 11(6):426–433 119. Beverly LJ, Capobianco AJ (2004) Targeting promiscuous signaling pathways in cancer: Another Notch in the bedpost. Trends Mol Med 10(12):591–598 120. Aplenc R, Lange B (2004) Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br J Haematol 125(4):421–434 121. Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32(5):651–662
a References 107 122. Lennard L, Lilleyman JS (1987) Are children with lymphoblastic leukaemia given enough 6-mercaptopurine? Lancet 2(8562): 785–787 123. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM (1987) Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41(1):18–25 124. Koren G, Ferrazini G, Sulh H, et al. (1990) Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 323(1):17–21 125. Schmiegelow K, Schroder H, Gustafsson G, et al. (1995) Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 13(2):345–351 126. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE (1995) A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci 92(4):949–953 127. Yates CR, Krynetski EY, Loennechen T, et al. (1997) Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126(8):608–614 128. McLeod HL, Krynetski EY, Relling MV, Evans WE (2000) Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14(4):567–572 129. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93(9):2817–2823 130. Relling MV, Rubnitz JE, Rivera GK, et al. (1999) High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354(9172):34–39 131. Relling MV, Yanishevski Y, Nemec J, et al. (1998) Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12(3):346–352 132. Chiusolo P, Reddiconto G, Casorelli I, et al. (2002) Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13(12):1915–1918 133. Taub JW, Matherly LH, Ravindranath Y, Kaspers GJ, Rots MG, Zantwijk CH (2002) Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia 16(4):764–765 134. Bernbeck B, Mauz-Korholz C, Zotz RB, Gobel U (2003) Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis. Klin Padiatr 215(6):327–331 135. Kishi S, Griener J, Cheng C, et al. (2003) Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 21(16):3084–3091 136. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A (2004) Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 4(1):66–72 137. Gorlick R, Cole P, Banerjee D, et al. (1999) Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation. Adv Exp Med Biol 457:543–550 138. Belkov VM, Krynetski EY, Schuetz JD, et al. (1999) Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 93(5):1643–1650 139. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100(10): 3832–3834 140. Krajinovic M, Costea I, Chiasson S (2002) Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 359(9311):1033–1034 141. Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M (2002) Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia 16(8):1437–1442 142. Brown L, Cheng JT, Chen Q, et al. (1990) Site-specific recombination of the tal-1 gene is a common occurrence in human T-cell leukemia. EMBO J 9(10):3343–3351 143. Bernard O, Lecointe N, Jonveaux P, et al. (1991) Two site-specific deletions and t(1;14) translocation restricted to human T-cell acute leukemias disrupt the 5' part of the tal-1 gene. Oncogene 6(8):1477–1488 144. Bernard O, Barin C, Charrin C, Mathieu-Mahul D, Berger R (1993) Characterization of translocation t(1;14)(p32;q11) in a T and in a B acute leukemia. Leukemia 7(10):1509–1513 145. Chen Q, Yang CY, Tsan JT, et al. (1990) Coding sequences of the tal-1 gene are disrupted by chromosome translocation in human T-cell leukemia. J Exp Med 172(5):1403–1408 146. Carroll AJ, Crist WM, Link MP, et al. (1990) The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 76(6):1220– 1224 147. Xia Y, Brown L, Tsan JT, et al. (1992) The translocation (1;14) (p34;q11) in human T-cell leukemia: Chromosome breakage 25 kilobase pairs downstream of the TAL1 protooncogene. Genes Chromosomes Cancer 4(3):211–216 148. Martin-Henao GA, Sureda A (1995) Translocation (1;14)(p34;q11) and trisomy 8 in a T-cell acute lymphoblastic leukemia patient. Cancer Genet Cytogenet 79(2):177–181 149. Hansen-Hagge TE, Schafer M, Kiyoi H, et al. (2002) Disruption of the RanBP17/Hox11L2 region by recombination with the TCRdelta locus in acute lymphoblastic leukemias with t(5;14) (q34;q11). Leukemia 16(11):2205–2212 150. Inaba T, Murakami S, Oku N, et al. (1990) Translocation between chromosomes 8q24 and 14q11 in T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet 49(1):69–74 151. Kasai M, Aoki K, Matsuo Y, Minowada J, Maziarz RT, Strominger JL (1994) Recombination hotspot associated factors specifically recognize novel target sequences at the site of interchromosomal rearrangements in T-ALL patients with t(8;14)(q24;q11) and t(1;14)(p32;q11). Int Immunol 6(7):1017–1025 152. Duro D, Bernard O, Della Valle V, Berger R, Larsen CJ (1995) A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11(1):21–29 153. Zutter M, Hockett RD, Roberts CW, et al. (1990) The t(10;14) (q24;q11) of T-cell acute lymphoblastic leukemia juxtaposes
Page 1 and 2:
E.H. Estey · S.H. Faderl · H. M.
Page 3 and 4:
E. H. Estey Department of Leukemia
Page 5 and 6:
VI Table of Contents 14 Philadelphi
Page 7 and 8:
VIII Contributors S. H. Faderl Depa
Page 9 and 10:
X Contributors D. Wartenberg Depart
Page 11 and 12:
Therapy of AML Elihu Estey Contents
Page 13 and 14:
a 1.2 · Standard Therapy 3 Table 1
Page 15 and 16:
a 1.2 · Standard Therapy 5 Table 1
Page 17 and 18:
a 1.2 · Standard Therapy 7 tween G
Page 19 and 20:
a 1.2 · Standard Therapy 9 Fig. 1.
Page 21 and 22:
a 1.2 · Standard Therapy 11 of tre
Page 23 and 24:
a 1.2 · Standard Therapy 13 Table
Page 25 and 26:
a 1.2 · Standard Therapy 15 permit
Page 27 and 28:
a References 17 19. Care RS, Valk P
Page 29 and 30:
a References 19 6-thioguanine in th
Page 31 and 32:
Acute Myeloid Leukemia: Epidemiolog
Page 33 and 34:
a 3.1 · Epidemiology 49 3.1.4 Gend
Page 35 and 36:
a 3.2 · Etiology 51 part of the in
Page 37 and 38:
a 3.2 · Etiology 53 for the develo
Page 39 and 40: a References 55 38. Crane MM, Stom
Page 41 and 42: Relapsed and Refractory Acute Myelo
Page 43 and 44: a 4.2 · Prognostic Factors in Pati
Page 45 and 46: a 4.3 · Treatment of Relapsed and
Page 47 and 48: a 4.4 · Hematopoietic Stem Cell Tr
Page 49 and 50: a 4.6 · Gemtuzumab Ozogamicin 65 T
Page 51 and 52: a 4.7 · Relapsed and Refractory Ac
Page 53 and 54: a 4.7 · Relapsed and Refractory Ac
Page 55 and 56: a References 71 The ability of immu
Page 57 and 58: a References 73 39. Vogler WR, McCa
Page 59 and 60: a References 75 95. Sievers EL, Lar
Page 61 and 62: Part II - Acute Lymphoblastic Leuke
Page 63 and 64: 78 Chapter 5 · Acute Lymphoblastic
Page 79 and 80: Molecular Biology and Genetics Meir
Page 81 and 82: a 6.3 · Structural Aberrations 97
Page 83 and 84: a 6.3 · Structural Aberrations 99
Page 85 and 86: a 6.5 · Molecular Aberrations 101
Page 87 and 88: a References 103 clear that homozyg
Page 89: a References 105 53. Chim CS, Tam C
Page 93 and 94: Diagnosis of Acute Lymphoblastic Le
Page 95 and 96: a 8.3 · Cytochemistry and Immunoph
Page 97 and 98: a 8.5 · Cytogenetic and Molecular
Page 99 and 100: a 8.5 · Cytogenetic and Molecular
Page 101 and 102: a References 127 including the reti
Page 103 and 104: a References 129 47. Kita K, Shirak
Page 105 and 106: Acute Lymphoblastic Leukemia: Clini
Page 107 and 108: a 7.3 · Diagnosis 111 or neoplasti
Page 109 and 110: a 7.3 · Diagnosis 113 Fig. 7.2. Hi
Page 111 and 112: a 7.3 · Diagnosis 115 The vast maj
Page 113 and 114: a References 117 dren: Biologic bas
Page 115 and 116: General Approach to the Therapy of
Page 117 and 118: a 9.3 · New Agents 133 dose methot
Page 119 and 120: a References 135 4. Gökbuget N, Ho
Page 121 and 122: 138 Chapter 10 · Recent Clinical T
Page 129 and 130: 146 Chapter 11 · Conventional Ther
Page 141 and 142:
158 Chapter 11 · Conventional Ther
Page 143 and 144:
ALL Therapy: Review of the MD Ander
Page 145 and 146:
a 12.2 · The Hyper-CVAD Regimen in
Page 147 and 148:
a 12.3 · Subset-Specific Approache
Page 149 and 150:
Treatment of Adult ALL According to
Page 151 and 152:
a 13.2 · Therapy for Younger (15-6
Page 153 and 154:
a 13.3 · Therapy of Ph/BCR-ABL-Pos
Page 155 and 156:
a 13.5 · Prognostic Factors 173 13
Page 157 and 158:
a References 175 Only patients with
Page 159 and 160:
Philadelphia Chromosome-Positive Ac
Page 161 and 162:
a 14.2 · Molecular Biology of the
Page 163 and 164:
a 14.3 · Treatment of Ph+ ALL 181
Page 165 and 166:
a 14.4 · Hematopoietic Stem Cell T
Page 167 and 168:
a References 185 2. Kurzrock R, Sht
Page 169 and 170:
a References 187 56. Mori T, Manabe
Page 171 and 172:
a References 189 acute lymphoblasti
Page 173 and 174:
192 Chapter 15 · Burkitt’s Acute
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
204 Chapter 16 · Treatment of Lymp
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
216 Chapter 17 · The Role of Allog
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
230 Chapter 18 · The Role of Autol
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
238 Chapter 19 · Novel Therapies i
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
248 Chapter 20 · Minimal Residual
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
264 Chapter 21 · Central Nervous S
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
276 Chapter 22 · Relapsed Acute Ly
Page 259 and 260:
278 Chapter 22 · Relapsed Acute Ly
Page 261 and 262:
Emergencies in Acute Lymphoblastic
Page 263 and 264:
a 23.5 · Hyperleukocytosis 283 LA
Page 265 and 266:
a 23.9 · Neurological Complication
Page 267 and 268:
a References 287 29. Hingorani AD,
Page 269 and 270:
Subject Index A aberrant methylatio
Page 271 and 272:
a Subject Index 291 CREB, see enhan
Page 273 and 274:
a Subject Index 293 MUD, see matche
show all

Acute Leukemias - Republican Scientific Medical Library

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?